Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Texas Attorney General Ken Paxton Sues Sanofi Over Alleged Healthcare Bribery Scheme 
Citigroup Private Bank Appoints Chad Reddy as West Market Executive in North America 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
BUENA, N.J., May 07, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, initially announced the Company would hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1st quarter 2018 financial results and business update. This call will be rescheduled for 8:30am ET on Tuesday, May 8, 2018.
The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to join the Teligent, Inc. call.
This call is available via webcast and can be accessed in the Investor Relations Section of Teligent, Inc.'s website at www.teligent.com.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
